

JUL 23 2004

**510(k) Summary  
L1-Pro System  
Pelikan Technologies, Corp.**

Prepared December 6, 2002

Product Name: L1-Pro System

Manufacturer: Pelikan Technologies, Corp.

Generic Name: Blood lancet

Classification Name: Manual surgical device for general use; blood lancet (Class I);  
Classification code: FMK; 21 CFR 878.4800

Contact Person: Jack S. Green, CQM  
Quality Assurance Manager  
Pelikan Technologies, Corp.  
1072 East Meadow Circle  
Palo Alto, California 94303

**A. Legally Marketed Predicate Device**

The L1-Pro System is substantially equivalent to the L1 System manufactured by Pelikan Technologies, Inc. and Autolet lite Clinisafe manufactured by Owen Mumford

**B. Device Description**

The L1-Pro System is a handheld, battery powered electronic lancing system used by a healthcare professional to obtain capillary blood samples in multi-patient clinical use. It consists of three major components, a reusable lancing control unit called the launcher, a disposable lancet disk with multiple sterile lancets, and disposable sterile isolation strips.

**C. Intended Use**

The L1-Pro System is an automatic blood lancet device for multi-patient clinical use by a healthcare professional to obtain a capillary blood sample.

**D. Substantial Equivalence**

The L1-Pro system is substantially equivalent to the intended use and technological characteristics of the predicate devices L1 and Autolet-lite Clinisafe.

**E. Performance Data**

Testing performed under the Design Control Process verified that the L1-Pro System performed according to specifications and is in compliance with all applicable performance standards.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

JUL 23 2004

Mr. Jack S. Green, CQM  
Quality Assurance Manager  
Pelikan Technologies Corp.  
1072 East Meadow Circle  
Palo Alto, California 94303

Re: K041665  
Trade/Device Name: L1-Pro System  
Regulation Number: 21 CFR 878.4800  
Regulation Name: Manual surgical instrument  
Regulatory Class: I  
Product Code: FMK  
Dated: June 9, 2004  
Received: June 21, 2004

Dear Mr. Green:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Mr. Jack S. Green, CQM

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>


Sincerely yours,

A handwritten signature in black ink, appearing to read "Celia M. Witten". The signature is written in a cursive style with a large initial "C" and "W".

Celia M. Witten, Ph.D., M.D.  
Director

Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure



### Indications for Use

510(k) Number (if known): K041665

Device Name: L1-PRO SYSTEM

Indications For Use:

**The L1-Pro System is an automatic blood lancet device for multi-patient clinical use by a healthcare professional to obtain a capillary blood sample.**


Prescription Use  X   
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
\_\_\_\_\_  
(Division Sign-Off)

**Division of General, Restorative,  
and Neurological Devices**

**510(k) Number** K041665